Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ciaran Patrick Kelly, M.D., M.B.

Co-Author

This page shows the publications co-authored by Ciaran Kelly and John Lamont.
Connection Strength

1.134
  1. Clostridium difficile infection. Annu Rev Med. 1998; 49:375-90.
    View in: PubMed
    Score: 0.185
  2. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother. 1996 Feb; 40(2):373-9.
    View in: PubMed
    Score: 0.162
  3. Clostridium difficile colitis. N Engl J Med. 1994 Jan 27; 330(4):257-62.
    View in: PubMed
    Score: 0.141
  4. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology. 1992 Jan; 102(1):35-40.
    View in: PubMed
    Score: 0.122
  5. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun. 2001 Apr; 69(4):2762-5.
    View in: PubMed
    Score: 0.058
  6. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest. 2000 Apr; 105(8):1147-56.
    View in: PubMed
    Score: 0.054
  7. Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut. 1999 Feb; 44(2):212-7.
    View in: PubMed
    Score: 0.050
  8. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol. 1997 12; 273(6):G1333-40.
    View in: PubMed
    Score: 0.046
  9. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997 Sep; 41(3):366-70.
    View in: PubMed
    Score: 0.045
  10. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother. 1997 Feb; 41(2):236-41.
    View in: PubMed
    Score: 0.044
  11. Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest. 1996 Aug 01; 98(3):641-9.
    View in: PubMed
    Score: 0.042
  12. A human antibody binds to alpha-galactose receptors and mimics the effects of Clostridium difficile toxin A in rat colon. Gastroenterology. 1996 Jun; 110(6):1704-12.
    View in: PubMed
    Score: 0.042
  13. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest. 1994 Mar; 93(3):1257-65.
    View in: PubMed
    Score: 0.036
  14. Clostridium difficile-associated diarrhea and colitis: pathogenesis and therapy. Int J Antimicrob Agents. 1993 Jul; 3(1):17-32.
    View in: PubMed
    Score: 0.034
  15. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993 Apr; 104(4):1108-15.
    View in: PubMed
    Score: 0.033
  16. Clostridium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. J Immunol. 1998 Jun 15; 160(12):6039-45.
    View in: PubMed
    Score: 0.012
  17. IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol. 1997 Aug; 273(2 Pt 1):G333-41.
    View in: PubMed
    Score: 0.011
  18. Ketotifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum. Gastroenterology. 1993 Sep; 105(3):701-7.
    View in: PubMed
    Score: 0.009
  19. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991 Apr; 118(4 Pt 1):633-7.
    View in: PubMed
    Score: 0.007
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.